Systemic delivery of drug-free polymeric nanoparticles reprograms innate immunity in a sex-dependent manner after spinal cord injury

Drug-free PLGA nanoparticles promote comparable locomotor recovery in both male and female mice after spinal cord injury by engaging distinct, sex-specific immune mechanisms—reducing macrophage infiltration in females via splenic accumulation and attenuating microglial activation in males via lesion accumulation—to ultimately converge on reduced scarring and enhanced remyelination.

The Gist

The Big Picture: A "Reset Button" for Spinal Cord Injuries

Imagine your spinal cord is a busy highway. When a car crash happens (a spinal cord injury), the road gets blocked by debris, and a chaotic traffic jam of emergency vehicles (immune cells) rushes in. While these emergency vehicles are trying to clean up the mess, they often cause more damage by crashing into each other and creating a giant, hard wall of construction barriers (scarring) that prevents traffic from ever flowing again.

For a long time, scientists have known that men and women react differently to these crashes. Men tend to have a specific type of "traffic jam," while women have a different one. This study asks: Can we use a smart, drug-free "traffic controller" (nanoparticles) to fix the road for both men and women, even if they need different instructions?

The Solution: The "Empty Delivery Truck"

The researchers used tiny, invisible spheres called nanoparticles made from a safe, biodegradable plastic (PLGA). Think of these as empty delivery trucks. They don't carry any medicine inside them; the truck itself is the medicine.

When injected into the bloodstream, these trucks travel to the injury site and interact with the immune system's "security guards" (white blood cells). The goal was to see if these trucks could calm down the chaos and help the road get repaired.

The Discovery: One Tool, Two Different Manuals

The most exciting finding is that the trucks worked for both men and women, helping them walk again. However, the way they worked was completely different, like using the same remote control to fix two different brands of TVs.

1. The Female "Detour" Strategy

• What happened: In female mice, the empty trucks mostly got stuck in the spleen (a filtering organ in the body) rather than going straight to the spinal cord injury.
• The Analogy: Imagine a traffic jam where the police (nanoparticles) set up a checkpoint at a nearby exit ramp (the spleen). They catch the angry, destructive trucks (inflammatory immune cells) before they can even reach the crash site.
• The Result: Because fewer angry trucks reached the injury, the damage was less severe. The female bodies were able to send in "repair crews" (Schwann cells) that built new bridges for the nerves to cross.

2. The Male "Direct Intervention" Strategy

• What happened: In male mice, the trucks went straight to the spinal cord injury itself.
• The Analogy: Here, the police didn't stop the trucks at the exit ramp; they drove right into the crash site and told the local security guards (microglia) to calm down immediately.
• The Result: The local guards stopped panicking and fighting, allowing the repair work to begin.

The Molecular Level: Speaking Different Languages

If you look at the "instruction manuals" (genes) inside the cells, the trucks spoke different languages to fix the problem:

• To the Females: The trucks turned off the "loudspeaker" for a specific type of chemical signal (eicosanoids) that causes inflammation.
• To the Males: The trucks turned off a different "loudspeaker" (NF-κB pathway) that triggers a different kind of inflammation.

Even though they turned off different switches, the end result was the same: The noise stopped, and the repair crews could get to work.

The Outcome: A Clearer Road

Because the nanoparticles calmed the immune system down in these specific ways:

1. Less Scarring: The hard, fibrous wall that usually blocks nerve growth was much smaller.
2. More Repair: New nerve fibers grew, and the insulation around them (myelin) was restored.
3. Better Walking: Both male and female mice walked much better than those who didn't get the treatment. In fact, the treatment erased the natural advantage females usually have over males in recovery, bringing everyone to the same high level of function.

Why This Matters

This study is a game-changer because it proves that one treatment can work for everyone, but we need to understand how it works differently for men and women.

Think of it like a universal key that opens two different locks. If you try to force the key into the lock without understanding the mechanism, it might break. But if you understand that the female lock needs a "detour" and the male lock needs "direct intervention," you can design better, smarter medicines for the future.

In short: These tiny, empty plastic balls acted as a universal peacekeeper for spinal cord injuries, calming the immune system in a sex-specific way to help both men and women walk again.

Technical Summary

1. Problem Statement

Spinal cord injury (SCI) triggers a secondary injury phase driven by neuroinflammation, leading to neuronal death, demyelination, and permanent functional deficits. While sex is a known biological variable influencing immune responses (with males typically exhibiting stronger microglial activation and females showing higher monocyte-derived macrophage (MDM) infiltration), most preclinical nanotherapeutic studies have been conducted exclusively in females. Consequently, there is a critical knowledge gap regarding how sex differences affect the biodistribution, cellular uptake, and therapeutic efficacy of immunomodulating nanoparticles (NPs). This study addresses whether drug-free polymeric NPs can effectively treat SCI in both sexes and if they utilize distinct immune mechanisms to achieve comparable functional outcomes.

2. Methodology

• Nanoparticle Formulation: The study utilized drug-free, carboxylated poly(lactic-co-glycolic acid) (PLGA) nanoparticles (approx. 500 nm diameter, negative surface charge). These were fabricated via emulsion solvent evaporation and stabilized with poly(ethylene-alt-maleic anhydride) (PEMA).
• Animal Model: Male and female C57BL/6 mice (6–10 weeks old) underwent a moderate contusion SCI (60-kDyn) at the T10 level. Sham controls received laminectomy only.
• Treatment Protocol: Mice received daily intravenous (tail vein) injections of PLGA NPs (50 mg/kg) or PBS control for 7 consecutive days, starting within 2 hours post-injury.
• Assessments:
  • Functional Recovery: Basso Mouse Scale (BMS) locomotor scoring and Open-Field Spontaneous Activity tests over 56 days.
  • Biodistribution: In vivo imaging of Cy5.5-labeled NPs in spinal cords and spleens at 7 days post-injury (DPI).
  • Immune Profiling: Flow cytometry of spinal cord and spleen cells at 1 and 7 DPI to quantify neutrophils, MDMs, microglia, and macrophage polarization (CD206+/CD163+).
  • Transcriptomics: NanoString nCounter Mouse Inflammation Panel and RT-qPCR to analyze gene expression changes.
  • Histology: Immunofluorescence staining for axonal regrowth (NF200), remyelination (MBP, P0), and scarring (Fibronectin, GFAP) at 56 DPI.

3. Key Contributions

• Sex-Dependent Mechanism Discovery: The study establishes that drug-free PLGA NPs achieve comparable functional recovery in both sexes but through fundamentally different immune reprogramming pathways.
• Biodistribution Divergence: It reveals that females sequester significantly more NPs in the spleen (reducing spinal cord accumulation), whereas males show higher NP accumulation directly at the lesion site.
• Targeted Immune Modulation: The research identifies that NPs primarily target infiltrating MDMs in females and resident microglia in males.
• Transcriptional Reprogramming: The study maps specific sex-dependent gene regulatory networks: eicosanoid signaling in females and NF-κB signaling in males.
• Therapeutic Equivalence: It demonstrates that despite distinct cellular and molecular mechanisms, the net result is the elimination of the functional recovery gap typically seen between untreated males and females.

4. Key Results

Functional Outcomes

• NP treatment significantly improved locomotor recovery (BMS scores) in both sexes compared to PBS controls.
• Crucially, untreated females naturally recovered better than untreated males. NP treatment eliminated this disparity, bringing male recovery to parity with female recovery.
• NP-treated males and females achieved comparable BMS sub-scores and spontaneous activity levels by 56 DPI.

Biodistribution & Immune Cell Dynamics

• Females: Showed high NP accumulation in the spleen and lower accumulation in the spinal cord. This correlated with a significant reduction in infiltrating MDMs and neutrophils at the lesion site and an increase in splenic myeloid cells.
• Males: Showed higher NP accumulation in the spinal cord lesion and lower splenic sequestration. This correlated with a significant reduction in resident microglial activation (CD45low/CD11b+), with minimal change in MDM infiltration.
• Polarization: Both sexes showed an increase in anti-inflammatory/pro-regenerative macrophage phenotypes (CD206+), but the magnitude was greater in females.

Transcriptomic Analysis (NanoString)

• Females: NP treatment preferentially downregulated pathways related to eicosanoid ligand-binding receptors (e.g., Ptgir, Ptgs2) and chemokine signaling. This aligns with the reduction in MDM infiltration.
• Males: NP treatment preferentially downregulated NF-κB signaling pathways (e.g., Tnf, Ccl3, Fxyd2). This aligns with the suppression of microglial activation.
• Convergence: While the specific pathways differed, the overall effect was a reduction in sex-specific inflammatory gene expression divergence, creating a more balanced microenvironment.

Tissue Repair and Scarring

• Remyelination: Both sexes showed increased axonal regrowth and oligodendrocyte-mediated remyelination. However, Schwann cell-mediated remyelination (P0+) was significantly enhanced only in females.
• Scarring: NP treatment significantly reduced fibrotic scarring (Fibronectin) in both sexes, with a more pronounced effect in females. Gliotic scarring (GFAP) remained largely unaffected by NP treatment.

5. Significance

• Translational Relevance: This study challenges the "one-size-fits-all" approach in nanomedicine. It proves that while a single therapeutic agent (drug-free PLGA NPs) can be effective for both sexes, the underlying biological mechanisms are sex-specific.
• Mechanistic Insight: The findings suggest that the therapeutic efficacy of PLGA NPs relies on their ability to engage the dominant inflammatory cell type in each sex: sequestering pro-fibrotic MDMs in the spleen for females, and directly suppressing reactive microglia in the lesion for males.
• Future Design: The results advocate for incorporating sex as a critical variable in the design of immunomodulatory nanotherapeutics. Understanding these divergent pathways (eicosanoid vs. NF-κB) allows for the rational design of next-generation NPs that could be tailored to maximize efficacy in specific patient populations.
• Clinical Implication: The ability of drug-free NPs to reduce fibrotic scarring and promote regeneration without exogenous drugs offers a promising, low-toxicity strategy for SCI treatment that addresses the complex, sex-dimorphic nature of post-injury inflammation.